The Board of Grand Pharmaceutical Group Limited announced that the Investigational New Drug applications of the Group's three innovative products in the sector of respiratory, severe disease and anti-infection, and ophthalmology were officially accepted by the National Medical Products Administration of the People's Republic of China recently. It is an important R&D progress of the Group in the field of the treatment in the above diseases. GPN00068 (APAD) is a small molecule compound with a novel mechanism of action independently developed by the Group.

By antagonizing a variety of pathogen-related molecules and inhibiting the excessive activation of immune cells, it is expected to prevent the occurrence and progression of sepsis from the source. The preclinical animal trial data shows that it has therapeutic effect in sepsis caused by both bacterial and viral infections. STC3141, the Group's another global innovative product, treats sepsis by antagonizing the body's excessive immune response.

These two products complement each other in their mechanism and can form a favorable synergistic effect in the treatment of severe diseases such as sepsis. Sepsis is a body's disorder response to infection leading to life-threatening organ dysfunction. There are about 48.9 million new cases of sepsis in the world every year, and the related death exceeds 11 million, accounting for one-fifth of the global death.

It is one of the major diseases that seriously threaten human health. However, there is no targeted drug that has been commercialized, and APAD and STC3141 are expected to fill the clinical gap in this therapeutic field. GPN00136 (BRM421) is a global innovative small molecule peptide eye drops product.

By accelerating the division and proliferation of limbal stem cells, it stimulates the repair of ocular surface. According to its phase II clinical study data completed in the United States, compared to cyclosporine eye drops currently commercialized for the treatment of dry eye, BRM421 has high safety and low irritation, as well as the potential to quickly alleviate the signs and symptoms of dry eye within two weeks.